Richard A. Onyett

LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

KuDOS Pharmaceuticals Ltd. discovers and develops pharmaceutical products. Its products are used to treat DNA damage sensing, signaling, viral disease, ischaemia, and repair to address unmet medical needs in cancer treatment. The company was founded by Stephen Jackson on December 12, 1997 and is headquartered in Cambridge, UK.

Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines.

Part of AbbVie, Inc., Epidauros Biotechnologie AG is a German company that specializes in pharmacogenomics research. The company is based in Bernried, Germany. Epidauros Biotechnologie was acquired by Clinical Data BV from Deutsche Effecten & Wechsel Beteiligungs AG on August 23, 2007 for $11.83 million.

Anthra Pharmaceuticals, Inc. is an American company.

Smithkline Beecham Plc develops and manufactures pharmaceutical products. The company markets pharmaceuticals for human and animal healthcare consumption, vaccines, over the counter medicines, health related consumer products, clinical laboratory testing services, disease management and pharmaceutical benefit management. It is headquartered in Brentford, UK.

ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom.